Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial (vol 19, pg 1315, 2018)

Dummer R.; Ascierto P. A.; Gogas H. J.

首页> 外文期刊>The lancet oncology >Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial (vol 19, pg 1315, 2018)

【24h】

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial (vol 19, pg 1315, 2018)

机译：Braf-突变体黑素瘤患者的整体生存接受Encorafenib Plus Binimetinib与vemurafenib或encorafenib（哥伦布）：多期，开放标签，随机，第3阶段试验（Vol 19，Pg 1315,2018）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2018年第10期|共1页
作者
Dummer R.; Ascierto P. A.; Gogas H. J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献

1. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial (vol 19, pg 1315, 2018) [J] . Dummer R., Ascierto P. A., Gogas H. J. The lancet oncology . 2018,第10期

机译：Braf-突变体黑素瘤患者的整体生存接受Encorafenib Plus Binimetinib与vemurafenib或encorafenib（哥伦布）：多期，开放标签，随机，第3阶段试验（Vol 19，Pg 1315,2018）
2. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial [J] . Dummer Reinhard, Ascierto Paolo A., Gogas Helen J., The lancet oncology . 2018,第5期

机译：Encorafenib Plus Binimetinib与Braf-Mutant Melanoma（哥伦布）患者的vemurafenib或encorafenib：多期，开放标签，随机阶段3试验
3. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2020,第期

机译：哥伦布的可耐受性和整体存活的更新：随机阶段3核酰胺in患者的随机阶段3试验的载体分析vemimetinib患者中的Binureafenib或Encorafenib患者
4. BIG BANG study (EPOC1703): multicentre proof-of-concept phase II study evaluating the efficacy and safety of combination therapy with binimetinib encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer [O] . Daisuke Kotani, Hideaki Bando, Hiroya Taniguchi, 2020

机译：BIG BANG研究（EPOC1703）：多中心概念验证II期研究评估与Binimetinibencorafenib和Cetuximab联合治疗BRAF非V600E突变型转移性结直肠癌的疗效和安全性
5. ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC) [O] . A. Grothey, R. Yaeger, D. Paez, 2019

机译：Anchor CRC：患有先前未经治疗的BRAF V600E-突变转移结直肠癌（MCRC）的患者中2，Open-Label（Enco），Binimetinib（Bini），Binimetinib（BINI），Binimetinib（BINI），加入西妥昔单抗（CETUX）的阶段2

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial (vol 19, pg 1315, 2018)

著录项

相似文献

相关主题

期刊订阅